Blue Oak Pharmaceuticals, Inc.
Novel small-molecule drugs for acute bipolar depression treatment using custom-designed chemotypes and deep behavioral profiling
- Sector
- Biotech
- Headquarters
- Waltham, MA
- Founded
- 2016
- Latest Form D
- $1.8M, Feb 2020
- Total capital
- $7.7M
- Federal grants
- $5.9M
- 5 awards · 2018–2023
- Rank in peer group#117 of 514
- Private capital raised
- $1.8M
- 1 Form D · last Feb 2020
- 80 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 10 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Next generation drugs for bipolar depression and maintenance$330K
- Federal grantHealth and Human S · Phase II · Next generation drugs for bipolar depression and maintenance$1.2M
- Federal grantHealth and Human S · Phase II · Next generation drugs for bipolar depression and maintenance$3M
- Private capital raisedForm D · SEC · 1st filing$1.8M
- Federal grantHealth and Human S · Phase I · Next Generation Drugs for Bipolar Depression and Maintenance$449K
- Federal grantHealth and Human S · Phase I · Next Generation Drugs for Bipolar Depression and Maintenance$899K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
18months
from Blue Oak Pharmaceuticals, Inc.’s first federal award to its first private round.
- First federal award · Sep 2018
- Health and Human S · $899K
- First Form D · Feb 2020
- $1.8M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#117 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Thomas H. LargeResearcherExecutive Officer, DirectorLinked by $5.9M in grants as PI
- Kerry Leigh SpearDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 10- PendingCompounds And Compositions For Treating Cns DisordersUSPTOApplication 17790526
- PendingCompounds And Compositions For Treating Cns DisordersUSPTOApplication 17790525
- PendingCompounds And Compositions For Treating Cns DisordersUSPTOApplication PCTUS2022021351
Show all 10 patent records
- Compounds And Compositions For Treating Cns DisordersApr 13, 2023 · Application 17790526Pending
- Compounds And Compositions For Treating Cns DisordersApr 13, 2023 · Application 17790525Pending
- Compounds And Compositions For Treating Cns DisordersApplication PCTUS2022021351Pending
- Compounds And Compositions For Modulating TAAR1Application 63164057Pending
- Compounds And Compositions For Treating Cns DisordersApplication PCTUS2020067301Pending
- Compounds And Compositions For Treating Cns DisordersApplication PCTUS2020067298Pending
- Compounds And Compositions For Treating Cns DisordersApplication 63128407Pending
- Compounds And Compositions For Treating Cns DisordersApplication 63128375Pending
- Compounds And Compositions For Treating Cns DisordersApplication 62956895Pending
- Compounds And Compositions For Treating Cns DisordersApplication 62956899Pending
Related companies, and why
- ELYSIUM THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- BLACKFYNN, INC.Similar federal contract value in Biotech · null in contracts
- Theratome Bio, Inc.Similar federal contract value in Biotech · null in contracts
- BasisSimilar federal contract value in Biotech · null in contracts
- SHIFA BIOMEDICAL CORPORATIONSimilar federal contract value in Biotech · null in contracts
- MDI THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .